Print Page     Close Window     

SEC Filings

8-K
BEIGENE, LTD. filed this Form 8-K on 01/07/2019
Entire Document
 

 

Strong Cash Position As of (Amounts in thousands of U.S. Dollars) September 30, 2018 (unaudited) December 31, 2017 (audited) Cash, cash equivalents, restricted cash and short - term investments $ 2,101,072 $ 837,516 Accounts receivable 37,372 29,428 Unbilled receivables 4,878 -- Working capital 1,991,771 763,509 Property and equipment, net 111,262 62,568 Total assets 2,408,627 1,046,479 Accounts payable 85,552 69,779 Accrued expenses and other payables 75,882 49,598 Bank loan 1 49,560 18,444 Shareholder loan 146,409 146,271 Total liabilities 425,196 362,248 Noncontrolling interest 12,985 14,422 Total equity $ 1,983,431 $ 684,231 21 U.S. GAAP; Cash, cash equivalents, restricted cash and short - term investments as of September 30, 2018 include approximately $14 3.16 million held by BeiGene Biologics, a 95% - owned joint venture. 1 The bank loan attributable to BeiGene Biologics totaled $40.82 million.

 


© 2016 BeiGene. All Rights Reserved.